Overview

DENdritic Cell Immunotherapy for Mesothelioma

Status:
Recruiting

Trial end date:
2023-02-15

Target enrollment:

Participant gender:

Summary

This study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to BSC alone.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Amphera BV

Collaborator:

TMC Pharma